Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine 3itacitinib 2Alemtuzumab 2thymoglobulin 1ruxolitinib 1romidepsin 1niraparib 1nelarabine 1fludarabine phosphate 1duvelisib 1Stem Cell Transplantation 1Interleukin-15 1INCB039110 1GRN163L peptide 1Everolimus 1Depsipeptides 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Prolymphocytic, T-Cell × INCB039110 × Clear all
NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡